Four persons were killed and 16 others injured due to an explosion in a chemical reactor at a pharmaceutical company's plant in Sangareddy district of Telangana on Wednesday, police and fire department officials said, adding that among the deceased is the firm's director. The blast occurred around 5 pm at the factory of SB Organics Ltd, located at Chandapur village of Hathnoora mandal of the district, and it led to a fire, they said. The plant is located about 40 km from Hyderabad International airport. The fire, which spread through the pharma unit's premises, was subsequently brought under control, the officials said. The deceased include the pharma firm's director and three workers, police said, but further details about the deceased were not immediately available. "The reactor exploded at the pharma company and people around it were thrown away in its impact...Four people have died," a senior police official told PTI. Sixteen others who suffered injuries in the incident have
AstraZeneca will pay $21 per Fusion share, a premium of more than 97% to the US-listed company's closing price on Monday
The Central Armed Police Forces Institute of Medical Sciences (CAPFIMS) on Saturday signed an MoU with the AIIMS to run CAPFIMS as a campus of the AIIMS here. The funds for procurement of medical equipment and furniture and the recurring cost towards operations and maintenance of the campus shall be provided to the All India Institute of Medical Sciences (AIIMS) by the Ministry of Home Affairs, an official statement said. Further, a part of the hospital beds in the campus shall be earmarked for providing healthcare services to all Central Armed Police Forces (CAPF) beneficiaries. The Union Cabinet has approved budgetary support of Rs 2,207.50 crore in the 15th Finance Commission cycle to run the CAPFIMS as a campus of AIIMS, New Delhi. Under the leadership of Prime Minister Narendra Modi, enhancing healthcare infrastructure in the country and providing world class health facilities to the people is one of the priorities of the government of India, the statement said. The MHA, unde
Braggadocio from startups is de rigueur, and plenty of ex-academics have started biotechnology firms, hoping to strike it rich on their one big discovery
Companies may get up to 375 ANDA approvals in 2023, more than last year's 355
The Food and Drug Administration warned consumers last month not to purchase or use store-brand eyedrops from Walmart Inc., CVS Health Corp., Target Corp. and other companies
The company exhibited a 2.66 per cent increase in revenue and was able to turn around the PAT by 2.09 per cent
Chief Minister Yogi Adityanath has envisioned increasing the state's contribution to the pharma industry from 2 per cent to 10-12 per cent
At 10:03 AM; shares of Valiant Labs were locked at the 5 per cent upper circuit at Rs 170.25, up 22 per cent over its issue price of Rs 140 per share.
Exposure to natural light may help treat and prevent type 2 diabetes, according to a small study. The research, presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Germany from October 2-6, carried out a range of metabolic tests on a group of people with type 2 diabetes when they were exposed to natural light and when they were exposed to artificial light and compared the results. "The misalignment of our internal circadian clock with the demands of a 24/7 society is associated with an increased incidence of metabolic diseases, including type 2 diabetes," said Ivo Habets of Maastricht University, the Netherlands, who co-led the research. "Natural daylight is the strongest zeitgeber, or environmental cue, of the circadian clock, but most people are indoors during the day and so under constant artificial lighting," said Habets. The yet-to-be peer-reviewed study involved 13 participants with an average age of 70 years who stayed in research
Cassiopea, a subsidiary of Cosmo, will receive an upfront payment of $5 million and agreed double-digit royalties on net sales
The PRIP scheme has two main components - the first one would focus on infrastructure building
The DCGI, in a letter dated September 4, has instructed state drug controllers to obtain the details from the firms under their jurisdiction
Five government hospitals and three private medical facilities have been put on "high alert" in view of the upcoming G20 Summit in the national capital, Delhi Health Minister Saurabh Bharadwaj has said. The Delhi health department has formed 80 teams of doctors and nursing staff, who will serve guests staying at hotels. Out of these teams, 75 teams will work in shifts, officials said on Wednesday. Bharadwaj convened a meeting at the Delhi Secretariat to take stock of healthcare arrangements in view of the Summit scheduled to be held from September 9 to 10. "In light of the G20 Summit, the Delhi government has placed five major government hospitals and three private hospitals on high alert to ensure the healthcare arrangements are in place. These include primarily Lok Nayak Hospital, GB Pant Hospital, GTB Hospital, Deen Dayal Upadhyay Hospital, and Babasaheb Ambedkar Hospital, along with private facilities Primus Hospital Chanakyapuri, Max Hospital Saket, and Manipal Hospital Dwarka,
Business Standard brings the top headlines at this hour
Lupin on Wednesday said its American subsidiary has received an approval from the US health regulator to market a generic product used for treatment of skin issues. New Jersey-based Novel Laboratories Inc has received the approval from the US Food and Drug Administration (USFDA) for Fluocinolone Acetonide Topical Oil, Lupin said in a statement. The product is the generic version of Hill Dermaceuticals Inc's Derma-Smoothe/FS Topical Oil. Lupin said the product will be manufactured at its Somerset facility in the US. As per the IQVIA MAT March 2023 data, Fluocinolone Acetonide Topical Oil had estimated annual sales of USD 9 million in the US. Lupin shares were trading 0.67 per cent down at Rs 981.65 apiece on the BSE.
More than 30 samples of drugs made by Delhi-based Synokem Pharmaceuticals Ltd have failed quality tests conducted by Indian regulators
Two other cough syrups made in India killed 19 children in Uzbekistan around December, according to the Uzbekistan government
Eye-drops made by Indiana Ophthalmics in Gujarat that have been under the scanner also feature in the list